The Medical Letter on Drugs and Therapeutics
Erenumab (Aimovig) for Migraine Prevention
June 18, 2018 (Issue: 1549)The FDA has approved erenumab-aooe (Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of migraine in adults. It is the first...more
- SD Silberstein et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1337.
- E Loder et al. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012; 52:930.
- Drugs for migraine. Med Lett Drugs Ther 2017; 59:27.
- AF Russo. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 2015; 55:533.
- ME Bigal et al. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 2013; 53:1230.
- PJ Goadsby et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377:2123.
- DW Dodick et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38:1026.
- S Tepper et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16:425.
- U Reuter et al. Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: results from the Phase 3b LIBERTY study. Presented at American Academy of Neurology 70th Annual Meeting, Los Angeles, CA, April 21-27, 2018. Available at: bit.ly/2Jvao1G. Accessed June 7, 2018.
- M Ashina et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology 2017; 89:1237.
- A MaassenVanDenBrink et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 2016; 37:779.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.